Properties of soluble glycoprotein VI, a potential platelet activation biomarker

References

• McGregor L, Martin J, McGregor JL. Platelet-leukocyte aggregates and derived microparticles in inflammation, vascular remodelling and thrombosis. Front Biosci 2006;11:830–837
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Moliterno DJ. The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs 2005;5:399–408
   PubMedGoogle Scholar
• Stoll G, Kleinschnitz C, Nieswandt B. The role of glycoprotein Ibalpha and von Willebrand factor interaction in stroke development. Hamostaseologie 2010;30:136–138
   PubMed Web of Science ®Google Scholar
• Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: Part IV: Matrix metalloproteinases and biomarkers of platelet activation. Circulation 2006;113:e382–e385
   PubMed Web of Science ®Google Scholar
• Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 2009;103:20A–26A
   PubMed Web of Science ®Google Scholar
• Burdess A, Michelsen AE, Brosstad F, Fox KA, Newby DE, Nimmo AF. Platelet activation in patients with peripheral vascular disease: Reproducibility and comparability of platelet markers. Thromb Res 2012;129:50–55
   PubMed Web of Science ®Google Scholar
• Gurney D, Lip GY, Blann AD. A reliable plasma marker of platelet activation: Does it exist? Am J Hematol 2002;70:139–144
   PubMed Web of Science ®Google Scholar
• Tsuji M, Ezumi Y, Arai M, Takayama H. A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem 1997;272:23528–23531
   PubMed Web of Science ®Google Scholar
• Leitinger B. Transmembrane collagen receptors. Annu Rev Cell Dev Biol 2011;27:265–290
   PubMed Web of Science ®Google Scholar
• Gardiner EE, Arthur JF, Kahn ML, Berndt MC, Andrews RK. Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase. Blood 2004;104:3611–3617
   PubMed Web of Science ®Google Scholar
• Gardiner EE, Karunakaran D, Shen Y, Arthur JF, Andrews RK, Berndt MC. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost 2007;5:1530–1537
   PubMed Web of Science ®Google Scholar
• Al-Tamimi M, Grigoriadis G, Tran H, Paul E, Servadei P, Berndt MC, Gardiner EE, Andrews RK. Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa. Blood 2011;117:3912–3920
   PubMed Web of Science ®Google Scholar
• Andrews RK, Karunakaran D, Gardiner EE, Berndt MC. Platelet receptor proteolysis: A mechanism for downregulating platelet reactivity. Arterioscler Thromb Vasc Biol 2007;27:1511–1520
   PubMed Web of Science ®Google Scholar
• Gardiner EE, Al-Tamimi M, Andrews RK, Berndt MC. Platelet receptor shedding. Methods Mol Biol 2012;788:321–339
   PubMedGoogle Scholar
• Berndt MC, Karunakaran D, Gardiner EE, Andrews RK. Programmed autologous cleavage of platelet receptors. J Thromb Haemost 2007;5:212–219
   PubMed Web of Science ®Google Scholar
• Stephens G, Yan Y, Jandrot-Perrus M, Villeval JL, Clemetson KJ, Phillips DR. Platelet activation induces metalloproteinase-dependent GP VI cleavage to down-regulate platelet reactivity to collagen. Blood 2005;105:186–191
   PubMed Web of Science ®Google Scholar
• Al-Tamimi M, Arthur JF, Gardiner E, Andrews RK. Focusing on plasma glycoprotein VI. Thromb. Haemost 2012;107:648–655
   Google Scholar
• Al-Tamimi M, Gardiner EE, Thom JY, Shen Y, Cooper MN, Hankey GJ, Berndt MC, Baker RI, Andrews RK. Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke 2011;42:498–500
   PubMed Web of Science ®Google Scholar
• Gardiner EE, Al-Tamimi M, Mu FT, Karunakaran D, Thom JY, Moroi M, Andrews RK, Berndt MC, Baker RI. Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura. J Thromb Haemost 2008;6:1175–1182
   PubMed Web of Science ®Google Scholar
• Nurden P, Tandon N, Takizawa H, Couzi L, Morel D, Fiore M, Pillois X, Loyau S, Jandrot-Perrus M, Nurden AT. An acquired inhibitor to the GPVI platelet collagen receptor in a patient with lupus nephritis. J Thromb Haemost 2009;7:1541–1549
   PubMed Web of Science ®Google Scholar
• Bigalke B, Stellos K, Weig HJ, Geisler T, Seizer P, Kremmer E, Pötz O, Joos T, May AE, Lindemann S, et al. Regulation of platelet glycoprotein VI (GPVI) surface expression and of soluble GPVI in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS). Basic Res Cardiol 2009;104:352–357
   PubMed Web of Science ®Google Scholar
• Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK. Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets 2009;20:143–149
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Naitoh K, Wada H, Ikejiri M, Mastumoto T, Ohishi K, Hosaka Y, Nishikawa M, Katayama N. Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy. Thromb Res 2014;133:440–444
   PubMed Web of Science ®Google Scholar
• Takayama H, Hosaka Y, Nakayama K, Shirakawa K, Naitoh K, Matsusue T, Shinozaki M, Honda M, Yatagai Y, Kawahara T, et al. A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex. J. Clin. Invest 2008;118:1785–1795
   PubMed Web of Science ®Google Scholar
• Morton LF, Hargreaves PG, Farndale RW, Young RD, Barnes MJ. Integrin alpha 2 beta 1-independent activation of platelets by simple collagen-like peptides: Collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for alpha 2 beta 1-independent platelet reactivity. Biochem J 1995;306:337–344
   PubMed Web of Science ®Google Scholar
• Mizushima S, Nagata S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 1990;18:5322
   PubMed Web of Science ®Google Scholar
• Okada H, Imai M, Ono F, Okada A, Tada T, Mizue Y, Terao K, Okada N. Novel complementary peptides to target molecules. Anticancer Res 2011;31:2511–2516
   PubMed Web of Science ®Google Scholar
• Ezumi Y, Uchiyama T, Takayama H. Molecular cloning, genomic structure, chromosomal localization, and alternative splice forms of the platelet collagen receptor glycoprotein VI. Biochem Biophys Res Commun 2000;277:27–36
   PubMed Web of Science ®Google Scholar
• Katayama M, Handa M, Araki Y, Ambo H, Kawai Y, Watanabe K, Ikeda Y. Soluble P-selectin is present in normal circulation and its plasma level is elevated in patients with thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome. Br J Haematol 1993;84:702–710
   PubMed Web of Science ®Google Scholar
• Wagner DD. The Weibel-Palade body: The storage granule for von Willebrand factor and P-selectin. Thromb Haemost 1993;70:105–110
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Kereiakes DJ, Serebruany VL. Soluble P-selectin is not a surrogate marker for platelet P-selectin: Evidence from a multicenter chest pain study group. J Thromb Thrombolysis 2000;10:15–22
   PubMed Web of Science ®Google Scholar
• Herter JM, Rossaint J, Zarbock A. Platelets in inflammation and immunity. J Thromb Haemost 2014;Sep15. doi:10.1111/jth.12730
   Google Scholar
• Aslam R, Speck ER, Kim M, Crow AR, Bang KW, Nestel FP, Ni H, Lazarus AH, Freedman J, Semple JW. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 2006;107:637–641
   PubMed Web of Science ®Google Scholar
• Andonegui G, Kerfoot SM, McNagny K, Ebbert KV, Patel KD, Kubes P. Platelets express functional Toll-like receptor-4. Blood 2005;106:2417–2423
   PubMed Web of Science ®Google Scholar
• Zhang G, Han J, Welch EJ, Ye RD, Voyno-Yasenetskaya TA, Malik AB, Du X, Li Z. Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol 2009;182:7997–8004
   PubMed Web of Science ®Google Scholar
• Gitz E, Pollitt AY, Gitz-Francois JJ, Alshehri O, Mori J, Montague S, Nash GB, Douglas MR, Gardiner EE, Andrews RK, et al. CLEC-2 expression is maintained on activated platelets and on platelet microparticles. Blood 2014;124:2262–2270
   PubMed Web of Science ®Google Scholar
• Gardiner EE, Thom JY, Al-Tamimi M, Hughes A, Berndt MC, Andrews RK, Baker RI. Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura. Br J Haematol 2010;149:625–628
   PubMed Web of Science ®Google Scholar
• Ungerer M, Rosport K, Bültmann A, Piechatzek R, Uhland K, Schlieper P, Gawaz M, Münch G. Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 2011;123:1891–1899
   PubMed Web of Science ®Google Scholar
• Wu B, Sun YN. Pharmacokinetics of Peptide-Fc fusion proteins. J Pharm Sci 2014;103:53–64
   PubMed Web of Science ®Google Scholar
• T Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233–241
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706–1717
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection. J Thromb Haemost 2007;5:230–237
   PubMed Web of Science ®Google Scholar
• Oqueli E, Hiscock M, Dick R. Clopidogrel resistance. Heart Lung Circ 2007;16:S17–S28
   PubMedGoogle Scholar